CASE STUDY | Your microbiome may be a riskfactor for disease A number of genes involved in susceptibility to inflammatory bowel disorders (IBDs), including Crohn disease and ulcerative colitis, have been identified. However, it is clear that other risk factors, both genetic and nongenetic, are important in triggering the onset of these diseases. Recent research has centered on understanding the role of the gut microbiome and its interactions with the host genome in IBD. It is known that the microbiome of those with IBD is different from that of those whose IBD is in remission, and it is also different from that of people who do not have IBD. These observations suggest that transfer of microbiota from unaffected individuals via fecal microbial transplantation (FMT) might be a successful treatment for IBD. This idea is supported by the use of FMT as an effective treatment in IBD individuals for a potentially life-threatening infection caused by the bacterium Clostridium difficile. Currently, four clinical trials are underway to evaluate the use of FMT as a treatment for IBD. If you had IBD, how would you react if your physician recommended that you enroll in one of these clinical studies to evaluate fecal transplants as a treatment?

Question

Want to see more full solutions like this?

Answer 1

Textbook Question

Chapter 18, Problem 1CS

CASE STUDY| Your microbiome may be a riskfactor for disease

A number of genes involved in susceptibility to inflammatory bowel disorders (IBDs), including Crohn disease and ulcerative colitis, have been identified. However, it is clear that other risk factors, both genetic and nongenetic, are important in triggering the onset of these diseases. Recent research has centered on understanding the role of the gut microbiome and its interactions with the host genome in IBD. It is known that the microbiome of those with IBD is different from that of those whose IBD is in remission, and it is also different from that of people who do not have IBD. These observations suggest that transfer of microbiota from unaffected individuals via fecal microbial transplantation (FMT) might be a successful treatment for IBD. This idea is supported by the use of FMT as an effective treatment in IBD individuals for a potentially life-threatening infection caused by the bacterium Clostridium difficile. Currently, four clinical trials are underway to evaluate the use of FMT as a treatment for IBD.

If you had IBD, how would you react if your physician recommended that you enroll in one of these clinical studies to evaluate fecal transplants as a treatment?

Expert Solution & Answer

Summary Introduction

To review:

As an individual with inflammatory bowel disorder(IBD), how one would react if recommended by a physician to participate in the clinical trial for IBD treatment.

Introduction:

IBD is an inflammatory disorder that has recently been associated with gut microbiome. Several genetic and non-genetic factors have been identified to be associated with IBD. Recent researches have suggested an important role of the microbiome and its interaction with the host genome in IBD patients. Research has supported the evidence that there is a difference in the gut microbiome of individuals with IBD and the ones who do not have. Therefore, transfer of microbiota from unaffected individuals throughfecal microbial transplantation (FMT) might be a successful treatment for IBD. To advocate this hypothesis, four clinical trials are undergoing.

Explanation of Solution

FMT is a therapy to transfer fecal microbiota from unaffected to the affected individual. This therapy has helped in treating a potentially life-threatening infection caused by bacterium Clostridiumdifficile.

Depending on the intensity of the disease, one must see whether it is a better option or not. In case IBD is detected at a very early age, one should not agree to undergo clinical trials. It is better to first been treated with conventional anti-inflammatory drugs. On the other hand, if the disease is chronic and no positive results have been seen with drugs, in such case one can opt to participate in the clinical trial in a hope to get rid of the disorder.

Conclusion

Therefore, it can be concluded that based on the degree of disease and the time period since its onset, it must be decided whether to participate or not in the clinical trials.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Students have asked these similar questions

Hi, I am quite confused by the microbiome Whole-genome Wide Association Study. What are the differences between Quantitative Trait Loci and Microbiome Trait Loci? Are they represent the location of SNPs itself?

A cell infected with lambda bacteriophage can follow one of two pathways: the lytic or lysogenic pathway. Describe the similarities and differences between the structure of cI and Cro, paying particular attention to the features that allow them to carry out their different functions.

COVID-19 Research Every year, the United States and the world suffer a serious outbreak of emerging, re emerging or endemic disease. Using documented and reliable sources on the internet, find information about COVID-19 and its history. Please also list the souces used. Part 1: The History of COVID-19- respond to ALL questions Who first documented it? what was the first listed causal agent? Are there any identified vectors? What are the symptoms? What were some of the early treatments? Who identified the virus and what is the virus named? Why does this outbreak have gotten such a strong foothold? 2: The Virus Describe the structure of this virus including: its genetic material the configuration/ structure of its protein capsid which cells it infects, how that infection takes place. list symptoms and complications that can arise. what the first identified strain was, and list the current strains and what mutations have occurred to create the new versions (in general - not a…

Answer 2

Textbook Question

Chapter 18, Problem 1CS

CASE STUDY| Your microbiome may be a riskfactor for disease

A number of genes involved in susceptibility to inflammatory bowel disorders (IBDs), including Crohn disease and ulcerative colitis, have been identified. However, it is clear that other risk factors, both genetic and nongenetic, are important in triggering the onset of these diseases. Recent research has centered on understanding the role of the gut microbiome and its interactions with the host genome in IBD. It is known that the microbiome of those with IBD is different from that of those whose IBD is in remission, and it is also different from that of people who do not have IBD. These observations suggest that transfer of microbiota from unaffected individuals via fecal microbial transplantation (FMT) might be a successful treatment for IBD. This idea is supported by the use of FMT as an effective treatment in IBD individuals for a potentially life-threatening infection caused by the bacterium Clostridium difficile. Currently, four clinical trials are underway to evaluate the use of FMT as a treatment for IBD.

If you had IBD, how would you react if your physician recommended that you enroll in one of these clinical studies to evaluate fecal transplants as a treatment?

Expert Solution & Answer

Summary Introduction

To review:

As an individual with inflammatory bowel disorder(IBD), how one would react if recommended by a physician to participate in the clinical trial for IBD treatment.

Introduction:

IBD is an inflammatory disorder that has recently been associated with gut microbiome. Several genetic and non-genetic factors have been identified to be associated with IBD. Recent researches have suggested an important role of the microbiome and its interaction with the host genome in IBD patients. Research has supported the evidence that there is a difference in the gut microbiome of individuals with IBD and the ones who do not have. Therefore, transfer of microbiota from unaffected individuals throughfecal microbial transplantation (FMT) might be a successful treatment for IBD. To advocate this hypothesis, four clinical trials are undergoing.

Explanation of Solution

FMT is a therapy to transfer fecal microbiota from unaffected to the affected individual. This therapy has helped in treating a potentially life-threatening infection caused by bacterium Clostridiumdifficile.

Depending on the intensity of the disease, one must see whether it is a better option or not. In case IBD is detected at a very early age, one should not agree to undergo clinical trials. It is better to first been treated with conventional anti-inflammatory drugs. On the other hand, if the disease is chronic and no positive results have been seen with drugs, in such case one can opt to participate in the clinical trial in a hope to get rid of the disorder.

Conclusion

Therefore, it can be concluded that based on the degree of disease and the time period since its onset, it must be decided whether to participate or not in the clinical trials.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Answer 3

Textbook Question

Chapter 18, Problem 1CS

CASE STUDY| Your microbiome may be a riskfactor for disease

A number of genes involved in susceptibility to inflammatory bowel disorders (IBDs), including Crohn disease and ulcerative colitis, have been identified. However, it is clear that other risk factors, both genetic and nongenetic, are important in triggering the onset of these diseases. Recent research has centered on understanding the role of the gut microbiome and its interactions with the host genome in IBD. It is known that the microbiome of those with IBD is different from that of those whose IBD is in remission, and it is also different from that of people who do not have IBD. These observations suggest that transfer of microbiota from unaffected individuals via fecal microbial transplantation (FMT) might be a successful treatment for IBD. This idea is supported by the use of FMT as an effective treatment in IBD individuals for a potentially life-threatening infection caused by the bacterium Clostridium difficile. Currently, four clinical trials are underway to evaluate the use of FMT as a treatment for IBD.

If you had IBD, how would you react if your physician recommended that you enroll in one of these clinical studies to evaluate fecal transplants as a treatment?

Expert Solution & Answer

Summary Introduction

To review:

As an individual with inflammatory bowel disorder(IBD), how one would react if recommended by a physician to participate in the clinical trial for IBD treatment.

Introduction:

IBD is an inflammatory disorder that has recently been associated with gut microbiome. Several genetic and non-genetic factors have been identified to be associated with IBD. Recent researches have suggested an important role of the microbiome and its interaction with the host genome in IBD patients. Research has supported the evidence that there is a difference in the gut microbiome of individuals with IBD and the ones who do not have. Therefore, transfer of microbiota from unaffected individuals throughfecal microbial transplantation (FMT) might be a successful treatment for IBD. To advocate this hypothesis, four clinical trials are undergoing.

Explanation of Solution

FMT is a therapy to transfer fecal microbiota from unaffected to the affected individual. This therapy has helped in treating a potentially life-threatening infection caused by bacterium Clostridiumdifficile.

Depending on the intensity of the disease, one must see whether it is a better option or not. In case IBD is detected at a very early age, one should not agree to undergo clinical trials. It is better to first been treated with conventional anti-inflammatory drugs. On the other hand, if the disease is chronic and no positive results have been seen with drugs, in such case one can opt to participate in the clinical trial in a hope to get rid of the disorder.

Conclusion

Therefore, it can be concluded that based on the degree of disease and the time period since its onset, it must be decided whether to participate or not in the clinical trials.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Answer 4

Textbook Question

Chapter 18, Problem 1CS

CASE STUDY| Your microbiome may be a riskfactor for disease

A number of genes involved in susceptibility to inflammatory bowel disorders (IBDs), including Crohn disease and ulcerative colitis, have been identified. However, it is clear that other risk factors, both genetic and nongenetic, are important in triggering the onset of these diseases. Recent research has centered on understanding the role of the gut microbiome and its interactions with the host genome in IBD. It is known that the microbiome of those with IBD is different from that of those whose IBD is in remission, and it is also different from that of people who do not have IBD. These observations suggest that transfer of microbiota from unaffected individuals via fecal microbial transplantation (FMT) might be a successful treatment for IBD. This idea is supported by the use of FMT as an effective treatment in IBD individuals for a potentially life-threatening infection caused by the bacterium Clostridium difficile. Currently, four clinical trials are underway to evaluate the use of FMT as a treatment for IBD.

If you had IBD, how would you react if your physician recommended that you enroll in one of these clinical studies to evaluate fecal transplants as a treatment?

Expert Solution & Answer

Summary Introduction

To review:

As an individual with inflammatory bowel disorder(IBD), how one would react if recommended by a physician to participate in the clinical trial for IBD treatment.

Introduction:

IBD is an inflammatory disorder that has recently been associated with gut microbiome. Several genetic and non-genetic factors have been identified to be associated with IBD. Recent researches have suggested an important role of the microbiome and its interaction with the host genome in IBD patients. Research has supported the evidence that there is a difference in the gut microbiome of individuals with IBD and the ones who do not have. Therefore, transfer of microbiota from unaffected individuals throughfecal microbial transplantation (FMT) might be a successful treatment for IBD. To advocate this hypothesis, four clinical trials are undergoing.

Explanation of Solution

FMT is a therapy to transfer fecal microbiota from unaffected to the affected individual. This therapy has helped in treating a potentially life-threatening infection caused by bacterium Clostridiumdifficile.

Depending on the intensity of the disease, one must see whether it is a better option or not. In case IBD is detected at a very early age, one should not agree to undergo clinical trials. It is better to first been treated with conventional anti-inflammatory drugs. On the other hand, if the disease is chronic and no positive results have been seen with drugs, in such case one can opt to participate in the clinical trial in a hope to get rid of the disorder.

Conclusion

Therefore, it can be concluded that based on the degree of disease and the time period since its onset, it must be decided whether to participate or not in the clinical trials.

Want to see more full solutions like this?

Subscribe now to access step-by-step solutions to millions of textbook problems written by subject matter experts!

Answer 5

Textbook Question

Answer 6

Textbook Question

Answer 7

Expert Solution & Answer

Summary Introduction

To review:

As an individual with inflammatory bowel disorder(IBD), how one would react if recommended by a physician to participate in the clinical trial for IBD treatment.

Introduction:

IBD is an inflammatory disorder that has recently been associated with gut microbiome. Several genetic and non-genetic factors have been identified to be associated with IBD. Recent researches have suggested an important role of the microbiome and its interaction with the host genome in IBD patients. Research has supported the evidence that there is a difference in the gut microbiome of individuals with IBD and the ones who do not have. Therefore, transfer of microbiota from unaffected individuals throughfecal microbial transplantation (FMT) might be a successful treatment for IBD. To advocate this hypothesis, four clinical trials are undergoing.

Explanation of Solution

FMT is a therapy to transfer fecal microbiota from unaffected to the affected individual. This therapy has helped in treating a potentially life-threatening infection caused by bacterium Clostridiumdifficile.

Depending on the intensity of the disease, one must see whether it is a better option or not. In case IBD is detected at a very early age, one should not agree to undergo clinical trials. It is better to first been treated with conventional anti-inflammatory drugs. On the other hand, if the disease is chronic and no positive results have been seen with drugs, in such case one can opt to participate in the clinical trial in a hope to get rid of the disorder.

Conclusion

Therefore, it can be concluded that based on the degree of disease and the time period since its onset, it must be decided whether to participate or not in the clinical trials.

Answer 8

Expert Solution & Answer

Summary Introduction

To review:

As an individual with inflammatory bowel disorder(IBD), how one would react if recommended by a physician to participate in the clinical trial for IBD treatment.

Introduction:

IBD is an inflammatory disorder that has recently been associated with gut microbiome. Several genetic and non-genetic factors have been identified to be associated with IBD. Recent researches have suggested an important role of the microbiome and its interaction with the host genome in IBD patients. Research has supported the evidence that there is a difference in the gut microbiome of individuals with IBD and the ones who do not have. Therefore, transfer of microbiota from unaffected individuals throughfecal microbial transplantation (FMT) might be a successful treatment for IBD. To advocate this hypothesis, four clinical trials are undergoing.

Explanation of Solution

FMT is a therapy to transfer fecal microbiota from unaffected to the affected individual. This therapy has helped in treating a potentially life-threatening infection caused by bacterium Clostridiumdifficile.

Depending on the intensity of the disease, one must see whether it is a better option or not. In case IBD is detected at a very early age, one should not agree to undergo clinical trials. It is better to first been treated with conventional anti-inflammatory drugs. On the other hand, if the disease is chronic and no positive results have been seen with drugs, in such case one can opt to participate in the clinical trial in a hope to get rid of the disorder.

Conclusion

Therefore, it can be concluded that based on the degree of disease and the time period since its onset, it must be decided whether to participate or not in the clinical trials.

Answer 9

Expert Solution & Answer

Answer 10

Expert Solution & Answer

Answer 11

Summary Introduction

To review:

As an individual with inflammatory bowel disorder(IBD), how one would react if recommended by a physician to participate in the clinical trial for IBD treatment.

Introduction:

IBD is an inflammatory disorder that has recently been associated with gut microbiome. Several genetic and non-genetic factors have been identified to be associated with IBD. Recent researches have suggested an important role of the microbiome and its interaction with the host genome in IBD patients. Research has supported the evidence that there is a difference in the gut microbiome of individuals with IBD and the ones who do not have. Therefore, transfer of microbiota from unaffected individuals throughfecal microbial transplantation (FMT) might be a successful treatment for IBD. To advocate this hypothesis, four clinical trials are undergoing.

Answer 12

Explanation of Solution

FMT is a therapy to transfer fecal microbiota from unaffected to the affected individual. This therapy has helped in treating a potentially life-threatening infection caused by bacterium Clostridiumdifficile.

Depending on the intensity of the disease, one must see whether it is a better option or not. In case IBD is detected at a very early age, one should not agree to undergo clinical trials. It is better to first been treated with conventional anti-inflammatory drugs. On the other hand, if the disease is chronic and no positive results have been seen with drugs, in such case one can opt to participate in the clinical trial in a hope to get rid of the disorder.

Answer 13

Conclusion

Therefore, it can be concluded that based on the degree of disease and the time period since its onset, it must be decided whether to participate or not in the clinical trials.

Answer 14

Ch. 18 - CASE STUDY | Your microbiome may be a risk factor...Ch. 18 - CASE STUDY|Your microbiome may be a riskfactor for...Ch. 18 - CASE STUDY | Your microbiome may be a risk...Ch. 18 - HOW DO WE KNOW? 1. In this chapter, we focused on...Ch. 18 - Review the Chapter Concepts list on page 345. All...Ch. 18 - Prob. 3PDQ Ch. 18 - Prob. 4PDQ Ch. 18 - Prob. 5PDQ Ch. 18 - Prob. 6PDQ Ch. 18 - Prob. 7PDQ

Concept explainers

Videos

Explanation of Solution

Want to see more full solutions like this?

Chapter 18 Solutions